The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
£3m EBIDTA. Repaying debt, and tax deferrals.... Sounds good to me.
"The objective to reduce net debt remains a priority for the Group and we have continued our rigorous focus on working capital efficiencies, cash conversation and cost management. This has enabled us to repay an additional £2.3 million of our term loan - over and above the scheduled quarterly payments. Our banking partner, HSBC, has waived the requirement of covenant measurements for the first half of the year ending March 2022.
Over the last 18 months, net debt has significantly reduced by £8.4 million; as of 30 September 2019, net debt was £11.1 million and at 31 March 2021 was £2.7 million, net of cash balances of £1.3 million. At 31 March 2021, Bilby had deferred £1.0 million VAT liabilities which post year-end, in agreement with HMRC, have started to be paid."
"Over the last 9 months, Microtox© PD units have achieved the ability to detect SARS-CoV-2 in wastewater.
..... In addition to SARS-CoV-2, Microtox© PD units have positively detected and identified E.coli bacteria in drinking water with 99.3% accuracy in 3.37 seconds. Current standard test results after sampling typically return in 2-5 days."
E. Coli is bacterial and so viral SARS-Cov-2 is a different ball game, but they are doing it and it is incredible. If they can achieve the same standard with SARS-Cov-2 then it's incredibly important. Clearly the investment is going in.
Well, I've just topped up at 128.08.
But I'm just so disappointed and saddened at the story of this last year. A year ago it was clear - before the phase II came out - that the company had a highly significant treatment. Only if the virus had something quite different would it not work. Well since then every trial has shown it DOES work. It works in the lungs, where it is designed to work! Hence that severe breathlessness is the key measure.
It is British. It has been in the public eye. Quite a few of us have written to our MPs about it. Every test and trial is positive. And 1 year on, and 3,183,177 deaths later [you can probably at least double that in reality], and we're still waiting for it to be deployed. NO urgency in government. Oh.....!
1. Severely breathless patients clearly benefit from the drug, and therefore are far less likely to become dangerously ill.
2. It can easily be administered at home.
Thus, to me, it's incredibly applicable to 3rd world, such as India at the moment.
My only question is how this would mix with dexamethasone, which may be applicable at the same stage of disease and be equally easy to dose at home.
Interesting. Money Week's cover story this week was Aviation, and they recommended that aircraft manufacturer based in Derby... "...sales....should grow by 17% this year. The group also has exciting products in the pipeline, including the UltraFan turbine, which is expected to boost fuel efficiency further - by up to 25% compared with earlier engines."
Hi Fantasy. Why did I think you were not a holder? I interpreted "Before anyone starts, no plans to buy, not touching vast with a barge pole" as you not being a holder. Looking at your other posts I do see that you hold, from a long time back. Well, I wish you good fortune. This could I suppose explode [either way], but yesterday I did something I have never done before: quickly sold what I had bought, at a loss. I hadn't done my research properly, didn't realise how dicey the management is. I have held companies to the bitter end before, with dubious management, for a story I believed in, and lost the lot. That's OK in a way, but it's simply a gamble, risk/reward that goes the wrong way. There's an element of that in every investment, and sometimes they go the right way. But do I need to do it with a BoD I have no confidence in? It makes it only about money, and I don't want to be like that. I don't want to be simply gambling, for the money. I invest in things I believe in, and I think that should include the management team as well. There's enough alternatives out there not to have to sit in what feels to me like a muddy pool. I realise some people won't think much of this, but all the best anyway! Best wishes to you all: I hope it does well.
In-long, stay away from my lawn!! Lol.
Otherwise, great post, thank you.
Fantasy thank you for all your time putting down your views, given that you are not a holder. Others too. You certainly know the history, and it's appreciated. At the moment this is exactly what I see a BB as being for: differing views, expressed with the reasoning, and without slanging. Usually the opposing views are few and far between, and tend to get shouted down. So thanks to all.
It's one to watch like a hawk...
Turnover nearly doubled, EBIDTA up nearly 6 X. That'll do. Expecting a jump today, after the long fall back.
Thanks for all the information, Rivaldo. Given the ongoing predominance and importance of tech it does look like this could continue to be a great share to be in for a long, long time. very pleased to be here. And I note that while one or two institutions have topsliced over recent months they are only creaming off profits, no one is selling down.
Nice to get off to a great start, Bing! Welcome.
Just seen that Simon Thomson in Investors Chronicle recommended it on the 16th, though the email didn't come through to me till this morning. Hence the jump, probably.
..... anyone know why?
Another fantastic RNS. "Cerillion has experienced its strongest ever six-month trading period, exceeding management expectations. Revenue for the first half ended 31 March 2021 is expected to total approximately £12.8m, a 25% increase on the same period last year (H1 2020: £10.2m) and adjusted EBITDA is expected to be approximately £4.8m, a 77% rise on the comparative period last year" et al.
The top 10 holders, including just one private individual, hold over 94% of shares. Keeping it nicely under wraps!
Cherokee, do you need new boots? :)
I hold both Haydale and DCTA. I'm pretty sure there's been no legal issues with Haydale (which has been a great investment for me - now it's our turn). They do overlap on shoe soles, Haydale are producing an additive that is being trialled at Bolflex. I'm not sure the additive is graphene or not, the RNS talks of "functionalised nano-enhanced rubber masterbatch". Their graphene is 'functionalised', so it may be a process applied to both, or use the functionalised graphene.
They are also producing graphene enhanced fabric for masks: "Haydale (AIM: HAYD), the global advanced materials group, is pleased to announce that, further to its announcement on 1 July 2020, IRPC Public Company Limited (IRPC) has now completed the development project with Haydale and started production of its new washable functionalised graphene-enhanced fabric mask. IRPC has now placed a follow-on order for 200Kg of Haydale's bespoke ink, with further orders anticipated. The face masks are currently being produced for use internally within the IRPC group.."
Directa's masks have a throwaway graphene-imbued insert that you replace. Not too great to be honest: my mask is very flimsy, was expensive, and will not last long. I'll have a load of inserts I can't use.
But long term I have great hopes for both companies.
Going by memory IQE produces the precursor wafer substrate, not the chips themselves. The present chip shortage is probably due to many causes but mostly carmakers shutting plants last year and therefore not ordering the same amount. Now they are competing with everyone else to catch up. What we are seeing now is the result of that low ordering of chips which will have translated back into the wafers with either low orders, or surplus inventory? If surplus inventory it implies it will take time to get back to normal.
Just my thoughts, I'm no expert.
"Tungsten Corporation PLC (AIM:TUNG), a leading provider of digital financial management products and software solutions, is pleased to announce that NTT Ltd., a leading global technology services company, has selected Tungsten, the leader in invoice digitisation, to support its goal of 90% invoice digitisation.
NTT will be the first Tungsten customer to implement Total AR, Total AP, and the Tungsten Workflow together. The combined solutions will solve de-centralised and paper-based financial challenges and speed consolidation of 15 in-country based finance operations teams into one Global Shared Service Centre. Anticipated benefits include information acceleration, resource efficiencies, streamlined processes, resulting in productivity gains.
As with all customers, Tungsten will provide NTT with ongoing and global compliance for 15 countries, including Germany, a key NTT market impacted by recent regulatory changes concerning electronic invoicing."
And today an RNS that Liontrust are up over 15%. That's £142million.
IMO Liontrust are one of the very best small/midcap institutions. People always think of their Special Sits fund, but I did very well over many years in their Smaller Companies fund. Low risk, sector beating, strong performance, every year. When I go back to funds they'll be the first port of call.